PTGDS: As a Specific Biomarker for Septic Cardiomyopathy

Area of Science:

• Biomarker Discovery
• Molecular Biology
• Genomics

Background:

• Septic cardiomyopathy (SCM) poses a significant clinical challenge, necessitating improved early identification and prognostic assessment strategies.
• Current diagnostic methods for SCM lack specificity, highlighting the need for novel biomarkers.

Purpose of the Study:

• To screen for specific biomarkers for Septic Cardiomyopathy (SCM).
• To identify potential research targets for early identification and prognosis assessment of SCM.

Main Methods:

• RNA sequencing of peripheral blood from sepsis patients and healthy volunteers.
• Intersection analysis of differentially expressed genes and heart-specific genes.
• Bioinformatic analyses including PPI, GO, and KEGG pathway enrichment.
• Survival analysis and ROC curve analysis for biomarker validation.
• Single-cell RNA sequencing for cellular localization of the target gene.

Main Results:

• Identified PTGDS as a potential core gene associated with sepsis prognosis.
• PTGDS demonstrated significant diagnostic value for sepsis with an AUC of 0.898.
• PTGDS expression was found to be lower in sepsis patients compared to healthy controls.
• Single-cell RNA sequencing indicated PTGDS expression in NK cells and T cells.

Conclusions:

• PTGDS is a novel diagnostic biomarker for sepsis with potential involvement in SCM.
• PTGDS represents a promising target for future diagnostic tool development and mechanistic research in sepsis.
• This discovery may aid in better clinical stratification of septic patients at risk for cardiac complications.